NCT06978738View on ClinicalTrials.gov

UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

November 30, 2028

Conditions
Systemic Lupus ErythematosusAutoimmune Hemolytic AnemiaMyasthenia GravisSystemic SclerosisANCA-Associated VasculitisInflammatory MyopathyIgG4-RD
Interventions
BIOLOGICAL

universal allogeneic anti-CD19/BCMA CAR T-cells

A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells

Trial Locations (1)

Unknown

Changzhou No.2 People's Hospital, Changzhou

All Listed Sponsors
lead

Changzhou No.2 People's Hospital

OTHER